Novamedix, Limited v. Ndm Acquisition Corporation and Vesta Healthcare, Inc.

166 F.3d 1177, 37 U.C.C. Rep. Serv. 2d (West) 918, 49 U.S.P.Q. 2d (BNA) 1613, 1999 U.S. App. LEXIS 1096, 1999 WL 35537
CourtCourt of Appeals for the Federal Circuit
DecidedJanuary 28, 1999
Docket97-1507
StatusPublished
Cited by31 cases

This text of 166 F.3d 1177 (Novamedix, Limited v. Ndm Acquisition Corporation and Vesta Healthcare, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Novamedix, Limited v. Ndm Acquisition Corporation and Vesta Healthcare, Inc., 166 F.3d 1177, 37 U.C.C. Rep. Serv. 2d (West) 918, 49 U.S.P.Q. 2d (BNA) 1613, 1999 U.S. App. LEXIS 1096, 1999 WL 35537 (Fed. Cir. 1999).

Opinion

EDWARD S. SMITH, Senior Circuit Judge.

Novamedix Limited (“Novamedix”) appeals the March 20, 1997 order of the District Court for the Southern District of Ohio, overruling a motion by Novamedix to enforce a consent judgment entered in a patent infringement suit brought by Novamedix against NDM. We hold that the settlement agreement incorporated into the consent decree is not a contract for the sale of goods and therefore the implied warranties of fitness and merchantability of UCC §§ 2-314 and 2-315 do not apply. Accordingly, we affirm the decision of the District Court.

Background,

NDM Acquisition Corp. (predecessor by merger to New Dimensions in Medicine, Inc.; together, “NDM”) and Novamedix are competitors in the market for medical footpumps. Footpumps improve the return of blood from the feet to the heart in bed-ridden patients by regularly inflating and deflating specially designed slippers on the patients’ feet. The improvement in circulation reduces blood clots and swelling and aids in healing of ulcers in such patients. The footpumps and slippers are regulated as medical devices by the Food and Drug Administration (FDA).

Novamedix sued NDM and Vesta Healthcare 1 in June of 1994, alleging infringement of Novamedix’s four U.S. Patents. 2 The par *1179 ties agreed to settle the patent infringement suit on the terms of a settlement agreement, which they entered into on March 5, 1996. Under the settlement agreement, NDM agreed to: (1) admit that it infringed Novam-edix’s patents and admit the validity and enforceability of those patents; (2) cease infringing the patents; (3) deliver its inventory of footpumps and slippers, along with its customer list, to Novamedix; (4) grant No-vamedix an exclusive license under NDM’s own patents; and (5) pay Novamedix $47,500.

For its part, Novamedix agreed to release NDM from further liability on its patent infringement claim, and agreed not to depose certain NDM employees in connection with ongoing, unrelated patent litigation. In addition, Novamedix was required to send a notice to all of NDM’s customers, informing them of the transfer of NDM’s inventory and stating that “Novamedix or its designee would like to service the needs of Customers on mutually accepted terms.” The settlement agreement also contained a New York choice-of-law provision.

The District Court for the Southern District of Ohio entered a consent judgment on March 11, 1996. In the consent judgment, NDM admitted the validity and enforceability of Novamedix’s patents, and admitted infringing the patents. The consent judgment also enjoined NDM from further infringement and incorporated the settlement agreement, requiring both parties to “adhere to the terms of the Agreement between them dated March 5, 1996.” The district court retained jurisdiction for enforcement of the decree.

NDM then delivered its inventory and customer list to Novamedix. The parties dispute whether they understood that Novame-dix intended to sell NDM’s inventory to NDM’s former customers. Whatever the parties’ understanding, the slippers in NDM’s existing inventory, and delivered to Novamedix, proved to be unsaleable because they did not meet FDA requirements. 3 On May 13, 1996, Novamedix filed a Motion to Enforce Final Judgment on Consent, arguing that under New York law the settlement agreement was a contract for the sale of goods and therefore subject to the implied warranties of merchantability and fitness of New York’s version of the Uniform Commercial Code (UCC) §§ 2-314 and 2-315.

On March 20, 1997, the district court overruled Novamedix’s motion. The district court framed the issue posed by Novamedix’s motion as whether the “Consent Judgment should be treated as a contract for the sale of goods for the purpose of implying the specified UCC warranties.” The district court, relying on United States v. Armour, 402 U.S. 673, 91 S.Ct. 1752, 29 L.Ed.2d 256 (1971), held that it should not. The district court found the language of the settlement agreement to be unambiguous, barring the use of extrinsic evidence in its interpretation. The court concluded that it was bound to hold the settlement agreement to its express terms, because Armour prohibited construing a consent decree so as to further the subjective purposes of one of the parties to the agreement. Since no express warranties were given by NDM in regard to the quality of its inventory, the district court refused to imply warranties by construing the settlement agreement as a contract tó sell goods.

We agree with the district court’s framing of the issue and, although our reasoning differs somewhat, we agree with the court’s ultimate conclusion. 4 We therefore affirm.

Jurisdiction and Standard of Review

The original claim for relief arose under the patent laws, 28 U.S.C. § 1338(a), and the consent judgment disposing of the case contained a provision retaining jurisdiction for purposes of enforcement. Thus, the or *1180 ders appealed from arise under the patent laws and we have jurisdiction over the appeal. See Gjerlov v. Schuyler Labs., Inc., 131 F.3d 1016, 1019 (Fed.Cir.1997).

In this case, the consent decree under consideration incorporates the terms of the parties’ settlement agreement, and it is the terms of the incorporated settlement agreement that are at the heart of the parties’ disagreement. Generally, interpretation of a settlement agreement is not an issue unique to patent law, even if arising in the context of a patent infringement suit. See Gjerlov, 131 F.3d at 1020. See also Sun Studs, Inc. v. Applied Theory Assocs., Inc., 772 F.2d 1557, 1561 (Fed.Cir.1985). In issues that are not unique to patent law, we apply the law of the appropriate regional circuit. Accordingly, we apply the law of the Sixth Circuit in this case.

The Sixth Circuit has held that both consent decrees and settlement agreements are construed in the same manner as other contracts. See Brown v. Neeb, 644 F.2d 551, 557 (6th Cir.1981) (“ ‘[S]ince consent decrees and orders have many of the attributes of ordinary contracts, they should be construed basically as contracts.’ ”) (quoting United States v. ITT Continental Baking Co., 420 U.S. 223, 236-237, 95 S.Ct. 926, 43 L.Ed.2d 148 (1975)); Bamerilease Capital Corp. v. Nearburg, 958 F.2d 150, 152 (6th Cir.1992) (“Settlement agreements are a type of contract and are therefore governed by contract law.... Wong v. Bailey,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tapp MFG, Inc. v. Speed UTV, LLC
M.D. North Carolina, 2026
Northern Bottling Co., Inc. v. PepsiCo, Inc.
5 F.4th 917 (Eighth Circuit, 2021)
Cardionet, LLC v. Mednet Healthcare Technologies, Inc.
146 F. Supp. 3d 671 (E.D. Pennsylvania, 2015)
Buckhorn Inc. v. Orbis Corporation
618 F. App'x 1000 (Federal Circuit, 2015)
Bennett Marine, Inc. v. Lenco Marine, Inc.
549 F. App'x 947 (Federal Circuit, 2013)
Alexx, Inc. v. Charm Zone, Inc.
484 F. App'x 476 (Federal Circuit, 2012)
Sanofi-Aventis v. Apotex Inc.
659 F.3d 1171 (Federal Circuit, 2011)
Schmidt v. Versacomp, Inc.
432 F. App'x 969 (Federal Circuit, 2011)
Sanofi-Aventis v. Sandoz, Inc.
405 F. App'x 493 (Federal Circuit, 2010)
Environmental Safety Consultants, Inc. v. United States
95 Fed. Cl. 77 (Federal Claims, 2010)
Ole Mexican Foods, Inc. v. Hanson Staple Co.
676 S.E.2d 169 (Supreme Court of Georgia, 2009)
Hanson Staple Co. v. OLE MEXICAN FOODS, INC.
666 S.E.2d 398 (Court of Appeals of Georgia, 2008)
Panduit Corp. v. Hellermanntyton Corp.
451 F.3d 819 (Federal Circuit, 2006)
Mag-Nif Inc. v. Royal Sovereign International, Inc.
168 F. App'x 432 (Federal Circuit, 2006)
Thatcher v. Kohl's Department Stores, Inc.
397 F.3d 1370 (Federal Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
166 F.3d 1177, 37 U.C.C. Rep. Serv. 2d (West) 918, 49 U.S.P.Q. 2d (BNA) 1613, 1999 U.S. App. LEXIS 1096, 1999 WL 35537, Counsel Stack Legal Research, https://law.counselstack.com/opinion/novamedix-limited-v-ndm-acquisition-corporation-and-vesta-healthcare-cafc-1999.